SHANDONG WOHUA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.52 CNY | +1.12% |
|
+7.62% | -25.54% |
| Sales 2022 | 1.01B 140M 11.68B | Sales 2023 | 910M 126M 10.47B | Capitalization | 3.5B 484M 40.32B |
|---|---|---|---|---|---|
| Net income 2022 | 107M 14.77M 1.23B | Net income 2023 | 58M 8M 667M | EV / Sales 2022 | 3.25 x |
| Net cash position 2022 | 277M 38.21M 3.19B | Net cash position 2023 | 401M 55.3M 4.61B | EV / Sales 2023 | 3.41 x |
| P/E ratio 2022 |
32.6
x | P/E ratio 2023 |
60.7
x | Employees | 1,353 |
| Yield 2022 * |
-
| Yield 2023 |
4.12% | Free-Float | 46.19% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.12% | ||
| 1 week | +7.62% | ||
| Current month | -6.80% | ||
| 1 month | -6.42% | ||
| 3 months | -20.28% | ||
| 6 months | -24.67% | ||
| Current year | -25.54% |
1 week
4.07
4.53
1 month
3.895.04
Current year
3.206.39
1 year
3.207.22
3 years
3.209.41
5 years
3.2013.11
10 years
2.9832.13
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Zi Zeng
PSD | President | 61 | 01/83/01 |
Jiong Wang
DFI | Director of Finance/CFO | 50 | 01/07/01 |
Bo Fang Liu
BRD | Director/Board Member | 47 | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Qin Gao
BRD | Director/Board Member | 55 | 10/22/10 |
Cai Xia Zhao
BRD | Director/Board Member | 54 | 17/17/17 |
Wen Jun Yin
CHM | Chairman | 59 | 17/17/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 4.52 | +1.12% | 5,499,832 |
| 25/24/25 | 4.47 | +1.13% | 4,767,345 |
| 24/24/24 | 4.42 | +1.61% | 5,809,100 |
| 23/24/23 | 4.35 | +3.33% | 7,663,400 |
| 22/24/22 | 4.21 | +0.24% | 6,574,909 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Shandong Wohua Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of Chinese traditional patent medicines. The Company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Gushu tablets for the treatment of middle-aged and senile osteoporosis, and Hedan tablets for promoting blood circulation and for the treatment of hyperlipidemia. The Company distributes its products in domestic market, mainly in East China, North China and Northeast China.
Sector
Pharmaceuticals
Calendar
27/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -25.54% | 360M | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 002107 Stock
